Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus.
To reliably infect a primate model for human immunodeficiency virus (HIV), approximately 10,000-fold more virus must be delivered vaginally than intravenously. However, the vaginal mechanisms that help protect against HIV are poorly understood. Here, we report that human cervicovaginal mucus (CVM), obtained from donors with normal lactobacillus-dominated vaginal flora, efficiently traps HIV, causing it to diffuse more than 1,000-fold more slowly than it does in water. Lactobacilli acidify CVM to pH approximately 4 by continuously producing lactic acid. At this acidic pH, we found that lactic acid, but not HCl, abolished the negative surface charge on HIV without lysing the virus membrane. In contrast, in CVM neutralized to pH 6 to 7, as occurs when semen temporarily neutralizes the vagina, HIV maintained its native surface charge and diffused only 15-fold more slowly than it would in water. Thus, methods that can maintain both a high lactic acid content and acidity for CVM during coitus may contribute to both vaginal and penile protection by trapping HIV before it can reach target cells. Our results reveal that CVM likely plays an important but currently unappreciated role in decreasing the rate of HIV sexual transmission.
Lai
Samuel K
SK
Department of Chemical and Biomolecular Engineering, Institute for NanoBioTechnology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, Maryland 21218, USA.
Hida
Kaoru
K
Shukair
Shetha
S
Wang
Ying-Ying
YY
Figueiredo
Anna
A
Cone
Richard
R
Hope
Thomas J
TJ
Hanes
Justin
J
D000818:Animals; D002460:Cell Line; D002584:Cervix Uteri / Q000382:microbiology / Q000821:virology; D004195:Disease Models, Animal; D005260:Female; D015658:HIV Infections / Q000635:transmission; D015497:HIV-1 / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D019344:Lactic Acid / Q000378:metabolism; D007778:Lactobacillus; D009093:Mucus / Q000382:microbiology / Q000821:virology; D013499:Surface Properties; D014621:Vagina / Q000382:microbiology / Q000821:virology; D014771:Virion / Q000378:metabolism
D019344:Lactic Acid
AIDS Res Hum Retroviruses. 1998 Apr;14 Suppl 1:S17-21
9581879
AIDS. 2003 Mar 7;17(4):455-80
12598766
Sex Transm Dis. 2003 Feb;30(2):107-9
12567165
AIDS. 2008 Jul 31;22(12):1493-501
18614873
J Reprod Fertil. 1973 Apr;33(1):69-75
4699448
Lancet. 2001 Nov 10;358(9293):1593-601
11716886
Virology. 2007 Apr 10;360(2):286-93
17123568
J Infect Dis. 2004 May 15;189(10):1785-92
15122514
Nat Med. 2003 Mar;9(3):343-6
12579198
Cell Immunol. 1994 Jun;156(1):77-94
8200044
Adv Drug Deliv Rev. 2009 Feb 27;61(2):86-100
19166889
Clin Diagn Lab Immunol. 1997 May;4(3):367-74
9144379
Adv Drug Deliv Rev. 2005 Jan 2;57(1):63-78
15518921
J Infect Dis. 2005 May 1;191(9):1403-9
15809897
Sex Transm Dis. 2003 Mar;30(3):257-61
12616147
J Exp Med. 1991 Jul 1;174(1):289-92
1647436
Am J Reprod Immunol. 2008 Jan;59(1):27-34
18154593
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11504-9
16061810
AIDS Patient Care STDS. 1999 Dec;13(12):747-51
10743538
Nat Rev Microbiol. 2003 Oct;1(1):25-34
15040177
Adv Drug Deliv Rev. 2009 Feb 27;61(2):158-71
19133304
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1482-7
17244708
PLoS One. 2009;4(1):e4294
19173002
J Virol. 2000 Jul;74(13):6087-95
10846092
Infect Immun. 1999 Oct;67(10):5170-5
10496892
Clin Infect Dis. 2007 Dec 15;45 Suppl 4:S287-92
18190301
Infect Dis Clin North Am. 2005 Jun;19(2):387-406
15963878
Microbes Infect. 2003 Jan;5(1):59-67
12593974
Clin Diagn Lab Immunol. 2000 May;7(3):515-8
10799472
J Infect Dis. 1997 Oct;176(4):960-8
9333154
BMC Infect Dis. 2005 Sep 30;5:79
16194280